Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is well-positioned for profitable and sustainable growth, with strong cash position and positive cash flow expected in fiscal year 2026. The company has a diverse product portfolio with Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. With a record topline beat in 1Q26 and broad-based revenue growth, we expect positive sales performance, with expectations of at least 20% growth and a 74-76% gross profit margin for fiscal year 2026. Additionally, new sales hires in 2025 and favorable coverage decisions from major insurers signal continued growth potential for the company.

Bears say

Axogen is facing risks such as potential competition, regulatory concerns, and technological obsolescence which may lead to lower-than-projected sales growth and an inability to achieve sustainable profitability. Additionally, the company may struggle to acquire new customers and penetrate new markets due to incomplete care guidelines in its most mature commercial market. Despite delivering double-digit year-over-year growth, Axogen's potential dilution risk and a comparable EV/Revenue multiple of 9.0x could result in a price objective of approximately $50 per share with approximately 53.2 million shares outstanding as of April 24, 2026 in its $2.9 billion total addressable market (TAM) of extremities.

AxoGen (AXGN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 8 analysts, AxoGen (AXGN) has a Buy consensus rating as of May 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.